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Abstract: Primary infection with human cytomegalovirus (HCMV) results in the 
establishment of a lifelong infection of the host which is aided by the ability of HCMV to 
undergo a latent infection. One site of HCMV latency in vivo is in haematopoietic 
progenitor cells, resident in the bone marrow, with genome carriage and reactivation being 
restricted to the cells of the myeloid lineage. Until recently, HCMV latency has been 
considered to be relatively quiescent with the virus being maintained essentially as a “silent 
partner” until conditions are met that trigger reactivation. However, advances in techniques 
to study global changes in gene expression have begun to show that HCMV latency is a 
highly active process which involves expression of specific latency-associated viral gene 
products which orchestrate major changes in the latently infected cell. These changes are 
argued to help maintain latent infection and to modulate the cellular environment to the 
benefit of latent virus. In this review, we will discuss these new findings and how they 
impact not only on our understanding of the biology of HCMV latency but also how they 
could provide tantalising glimpses into mechanisms that could become targets for the 
clearance of latent HCMV. 
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1. Introduction 
Human Cytomegalovirus (HCMV) remains a major cause of disease in a number of patient 
populations who have compromised immune systems, as well as providing an increasing threat to 
critically ill immuno-competent patients [1–4]. These pathologies associated with opportunistic 
HCMV infections can be, in part, associated with a key characteristic of the virus: the ability to 
establish lifelong latent infection of the human host and, crucially, reactivate [2,5]. A wealth of studies 
from a number of laboratories using naturally latently infected cells has led to an informed consensus 
that the cells of the myeloid lineage represent at least one important site of HCMV latency, 
persistence, and reactivation (reviewed in [6]). Thus, at a cellular level, there is a clear and intimate 
link between myeloid differentiation and natural HCMV reactivation [7–14]. Furthermore, the use of 
experimental infection of non-permissive primary cells and cell lines in vitro are generating snapshots 
of the complex regulation of HCMV gene expression at a molecular level [15–25]. However, these 
studies have focussed predominantly on the regulation of major immediate early (MIE) gene 
expression because the critical switch to a reactivating phenotype is dependent on the triggering of 
MIE gene expression from quiescence. 
In many cases, the species specificity of HCMV has driven these analyses to be performed in 
experimental cell culture models and, ultimately, on tissue derived from healthy HCMV seropositive 
individuals which has then been analysed ex vivo. As a result, the mechanisms that control HCMV 
latency and persistence in vivo, at an organism level, have relied on the extrapolation of studies 
performed in vitro or using animal model surrogates such as murine CMV [26]; guinea pig CMV [27] 
and, more recently, non-human primate CMV strains [28]. Consequently, the inability to perform 
analogous studies in humans has likely contributed to the perception that HCMV latency is essentially 
a relatively quiescent infection. However, as techniques for studying HCMV at a molecular level have 
become increasingly powerful, it is now emerging that latent HCMV infection profoundly modulates 
the latently infected cell and the surrounding cellular environment. These effects act in concert to 
maintain latent carriage and this depends on, at least in part, the expression of a subset of virally 
encoded gene products.  
In this short review, we will examine our current knowledge of HCMV latency with particular 
emphasis on recent data which suggest that HCMV imparts a distinctive signature on latently infected 
cells. These latency-associated changes underpin the successful persistence of this virus in vivo and, 
importantly, could direct novel therapeutic strategies to target latency and reactivation of this 
important human pathogen.  
2. Background—HCMV Latency and Reactivation 
Following primary infection, HCMV establishes a latent infection of the CD34+ haematopoietic 
cell population in the bone marrow [29,30]. The prevailing view is that, ultimately, the major 
immediate early promoter (MIEP) is profoundly suppressed in these cells [6] and that this is achieved 
through cellular transcriptional repressors directing histone-modifying enzymes to impart repressive 
post-translational modifications of MIEP-associated histones [6]. During latency, the chromatin 
structure of the MIEP bears all the hallmarks of transcriptional repression: tri-methylation of histone H3 
(lysine 9 and 27) and recruitment of heterochromatin protein-1 (HP-1) coupled with a concomitant 
Viruses 2013, 5 2805 
absence of histone acetylation on histone H4 [11,16,17,25]. Consequently, HCMV MIE gene 
expression, and lytic gene expression in general, is profoundly repressed in CD34+ progenitor cells. 
This chromatin phenotype is maintained in the monocyte cells derived from these progenitors [11,31] 
and it is only upon cellular differentiation that robust IE gene expression is observed [7,8,11,12,32]. 
The detection of IE gene expression in dendritic cells (DCs) is consistent with the histone 
modifications present at the MIEP in these terminally differentiated myeloid cells [11,31]. For 
instance, HP-1 is no longer associated with the MIEP—likely due to extensive de-methylation of histones 
at lysine residue 9 (methylation at this residue being important for HP-1 binding to chromatin [33]) and, in 
these cells, the MIEP is associated with predominantly acetylated histones. Thus, the presence of 
repressive or activatory chromatin marks around the MIEP correlates with the expression of viral 
major IE RNA and the latency/reactivation phenotype of the virus [11,31]. Importantly, and consistent 
with molecular analyses, infectious HCMV progeny cannot be recovered from myeloid progenitor 
cells i.e., CD34+ cells or granulocyte–macrophage progenitors (GMPs) unless they are co-cultured 
under conditions that promote cellular differentiation or activation [9,11,34]. Analogous models of 
histone-mediated regulation of viral lytic gene expression also underpin studies of herpes simplex 
virus and Epstein–Barr virus and thus represent a common unifying theme in the biology of 
herpesvirus latency and reactivation [35,36].  
The molecular model of HCMV latency in the myeloid lineage, derived from analyses of natural 
latency, has been reviewed extensively elsewhere [6,37,38] and has helped provide an initial 
understanding of the underlying mechanism for the differentiation-dependent reactivation of HCMV. It 
is worth noting, however, that other studies using experimental infection models of latency and 
reactivation have essentially recapitulated the key observations made with natural models of latent 
infection and this gives confidence that wider studies involving experimentally latent models will have 
in vivo relevance. 
2.1. The Transcriptional Landscape of Latent HCMV 
HCMV encodes anywhere between 170 and 751 ORFs all of which are believed to be expressed at 
some stage during lytic infection [39,40]. Furthermore, the virus also encodes a number of microRNAs 
(miRNAs) which, during lytic infection, have been shown to target and regulate both cell and viral 
gene expression [41–43]. In contrast, the transcriptional landscape in latency is less clear. The earliest 
studies identified a number of transcripts arising from the MIE region of HCMV but no function was 
assigned to them [44,45]. Furthermore, deletion of the putative ORFs encoded by these latency-associated 
transcripts appeared to have little effect on HCMV latency in vitro [46]. As such, it was speculated that 
HCMV could exist in latency in a relatively quiescent state and that the normal transit and 
differentiation of latently infected CD34+ cells into the periphery was sufficient to trigger HCMV 
reactivation. Indeed, transcriptional quiescence during latency would provide the ideal mechanism for 
evasion of the robust immune responses known to be present in HCMV seropositive individuals [47]. 
However, a number of aspects of the known biology of HCMV are at odds with the view that HCMV 
is maintained in a totally quiescent state. For instance, if virus is carried long-term in the myeloid 
lineage, how is the latent genome maintained in cells which will, at least at some stage of their 
lifespan, proliferate? Although no latent origin of replication has been definitively identified for 
HCMV, it has been suggested that a mutation in the MIE region had a carriage defect during latency in 
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GMPs [48] and more recent work has suggested UL84 may act to maintain viral sequences [25]. 
Furthermore, an overt characteristic of HCMV latency is the carriage of the viral genome in the cells 
of the myeloid lineage and, particularly, the monocyte lineage [49–51] but not lymphocyte or 
polymorphonuclear cells [50] despite the fact that latent infection is seeded in a pluripotent progenitor 
cell type [29,30]. Potentially, this could be explained in alternative ways: the virus actively promotes 
myelopoiesis of infected CD34+ cells or, HCMV may preferentially promote the survival of myeloid 
committed progenitors or, finally, HCMV cannot combat anti-viral mechanisms in cells committed to 
the lymphoid lineage. Arguably, all these scenarios suggest an active process involving viral  
latency-associated functions during latent infection. 
A number of studies over the last 10 years or so have applied increasingly sensitive techniques to 
determine whether viral gene expression occurs during latent infection. Two independent microarray 
analyses identified a number of transcripts expressed during experimental latency [34,52] and, 
importantly, some have been subsequently confirmed during natural latency; including UL138,  
UL81-82ast (LUNA), as well as a splice variant of UL111A, which encodes a viral interleukin 10 
(vIL-10) termed LAcmvIL-10 [24,53–55]. These, and subsequent studies, have also shown that the 
initial infection of undifferentiated myeloid cells with HCMV to establish experimental latency results 
in a burst of temporally dysregulated viral transcription from a number of gene loci, including MIE 
gene expression, at very early times post infection [25,32,34]. However, it remains unclear what this 
means in the context of latent infection. It is tempting to speculate that this gene expression is 
important for preparing the cell for latency—akin to that proposed for the establishment of EBV 
latency [56]. However, there is no evidence, as yet, that cells which initially express lytic antigens go 
on to establish long-term latency. It is possible that the extremely high MOIs used to establish latent 
infections in vitro results in a sub-population of lytically or abortively infected cells which are, 
ultimately, unviable and die, leaving the true latent population.  
Regardless, what is generally accepted is that HCMV has a very distinct transcriptional profile 
during latent infection, quite different from lytic infection. The expression of a number of viral genes 
has now been described during latency and these are summarised in Table 1. For the remainder of this 
review, we will focus on emerging stories regarding the manipulation of latently infected cells by 
HCMV and how, in some instances, viral gene products may contribute to this. 
Table 1. Gene products and functions during latency and lytic infection. 
Gene Product  Latent Function Lytic Function References 
CLTs Unknown Regulation of anti-viral 2’5’ OAS 
expression (ORF94) 
[44–46,57] 
UL138 Regulation of TNFRI (up) and MRP1 
(down), repression of the MIEP(?) 
Regulation of TNFRI (up) and 
MRP1 (down), virus maturation 
(133-138 locus) 
[53,58–61] 
UL81-82ast Promotes UL138 gene expression.  Unknown [24,55,62] 
LAvIL-10 Down-regulation of MHC class II 
expression, immune evasion 
Unknown—cmvIL-10 expressed 
during lytic infection 
[54,63] 
Lnc4.9 Binds Polycomb repressor complex 2, 
Silencing of the MIEP 
Unknown [25] 
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Table 1. Cont. 
Gene Product  Latent Function Lytic Function References 
UL84 Genome maintenance DNA replication, UTPase 
activity, transcriptional 
regulation 
[25,64–67] 
US28 Unknown GPCR, induces cell signalling and 
cell migration, agonist of the MIEP 
[68–74] 
UL144 Unknown TNF superfamily member, hijacks 
NF-kB signalling, immune 
evasion? 
[75–78] 
3. Mechanisms Targeted during HCMV Latency 
3.1. Viral Evasion of Cell Death 
Pro-death signals in response to infection represent a very significant obstacle for many pathogens. 
Consequently, key players in the cellular apoptotic response become important targets for the  
virus—and HCMV is no exception. HCMV encodes an impressive armoury of anti-apoptotic functions 
that it expresses throughout lytic infection and which all contribute to efficient virus infection [79–84]. 
However, there is no evidence that any of these already-described anti-apoptotic viral genes associated 
with lytic infection are also expressed during latency. Clearly, if the virus was to be carried truly 
silently during latency then, arguably, there would be little requirement for any increased protection 
from cell death. However, it is becoming increasingly evident that HCMV does actively modulate 
multiple functions of the latently infected cell and that these, in effect, stress the cell to the point that 
viral functions are needed to protect the latently infected cell from such stress-induced pro-death signals.  
In the context of infection, be it latent or lytic, the initiation of cell death can arise at the earliest 
point of infection: at entry [85]. Pathogen recognition receptors (PRRs) can detect pathogen-associated 
molecular patterns (PAMPs), triggering cell death—and this is an important part of an intrinsic 
immune response [85]. Clearly, during lytic infection, the rapid expression of virally encoded  
anti-apoptotic proteins could quickly provide protection against such extrinsic death response signals [80]. 
However, during HCMV infection of cells destined to become latently infected with the associated 
suppression of the lytic transcription programme, it appears that virus binding, in itself, activates cell 
survival signals [86,87]. This occurs in both CD34+ cells and CD14+ cells, albeit with the 
employment of different signalling pathways in the two cell types as well as cell-specific differences in 
the duration of the survival response. Nevertheless, the up-regulation of an important cellular  
anti-apoptotic protein, MCL-1 [88], appeared to be important for protection in both cell types [86,87]. 
Thus, although the exact mechanisms of protection varied in these different cell types, the outcome 
was the same.  
The transitory nature of the ERK-MAPK dependent survival signal observed in CD34+ cells [86] 
argues that is likely to be important for overcoming the initial death signals triggered by cellular 
recognition of virus shortly after binding and/or entry. Consequently, it could be argued that long-term 
anti-death signals may not be required by a virus which is truly silenced in latency. However, recent 
work suggests that long-term anti-death signals may be important during latent infection with HCMV 
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(Figure 1). For instance, experimental latent infection of granulocyte–macrophage progenitors has 
been shown to result in long-term up-regulation of PEA-15 RNA [89]. As PEA-15 is an anti-apoptotic 
factor that blocks both TNFR1 and Fas-L triggered apoptosis [90], clearly its up-regulation could be 
part of a protective response mediated by latent infection. Consistent with this, latently infected 
CD34+ cells are protected from FAS-L induced cell death [91]. Furthermore, given that it has been 
shown that the UL138 gene product up-regulates TNFR1 expression during lytic [59,60] and latent 
infection [61], potentially sensitising latently infected cells to TNFR1 mediated apoptosis, the 
concomitant up-regulation of PEA-15 would be a sensible pro-survival strategy. Other preliminary 
data from the Sinclair laboratory has also shown that a number of other cellular proteins with potent 
anti-apoptotic function are up-regulated in latently infected CD34+ cells (J.S. unpublished data) and 
this includes the PEA-15 protein, further supporting a model by which induction of PEA-15 during 
latent infection, at least in part, protects latently infected cells from pro-death signals. Furthermore, it 
is likely that these effects are driven by secreted products in the latency-associated secretome [92], 
since inhibition of latency-induced cellular IL-10 was sufficient to block this survival effect [91]. 
Figure 1. Protection of latently infected cells from cell death. CD34+ cells latently infected 
with HCMV down-regulate the expression of mir92a. A key target of miRNA is the 
GATA-2 transcription factor which, consequently, is up-regulated. This promotes 
increased transcription of cellular (IL-10) and viral (LUNA) genes. LUNA expression 
promotes UL138 gene expression—a gene product shown to up-regulate cell surface levels 
of TNFRI, a potentially pro-apoptotic signalling factor. However, HCMV also up-regulates 
a number of anti-apoptotic factors including PEA-15. This occurs, in part, via the 
expression of IL-10 and potentially could provide a mechanism to protect cells from 
extrinsic cell death signalling. 
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3.2. Viral Evasion of the Immune Response during Latent Infection 
HCMV infection is known to generate a robust T cell response in vivo with between 0.5 and 10% of 
all cytotoxic T lympohcytes (CTLs) recognising HCMV antigens [47]. The CTL response to HCMV is 
dominated by two abundant viral antigens—pp65 and IE72 [47], although CTLs which recognise 
most, if not all, lytic antigens have been detected [93]. Pertinent to this review is that significant T cell 
responses against antigens also expressed during latency are present in healthy HCMV carriers [94,95] 
and thus, in theory, a latently infected cell should be visible to these T cells. However, recent work 
suggests that latent infection results in a number of mechanisms which act in concert to disrupt these T 
cell responses, thereby preventing clearance of latently infected cells by the adaptive arm of the host 
immune response (Figure 2). 
A recent analysis of experimentally latently infected CD34+ cells detected a unique cell secretome 
signature associated with latency [92]. Intriguingly, this secretome was observed to promote the 
migration of Th1 CD4+ T cells to the latently infected cell. However, the anti-viral effector functions 
of these recruited cytotoxic T cells was countered by the concomitant latency-associated expression of 
two key cellular cytokines, transforming growth factor—beta (TGF-) and interleukin-10 (cIL-10). 
Both TGF- and cIL-10 have profound immune-modulatory capacity [96] and, consistent with this, 
blocked the CD4+ T effector functions [92]. Although the exact mechanisms that resulted in  
up-regulated expression of TGF- and cIL-10 during latency are unclear, elevated cIL-10 production 
was observed to be, at least partly, dependent on the up-regulation of the cellular GATA-2 
transcription factor resulting from a concomitant down-regulation of the cellular microRNA mir92a [91]. 
Furthermore, other recent work has illustrated that a proportion of the CD4+ T cell response directed 
against latent antigens consists of T regulatory (Treg) cells [95]. This study in healthy donors showed 
that, whilst cytotoxic CD4+ T cell responses against latent antigens were detectable, they were 
dominated by IL-10 expressing Treg cells. Consequently, the recruitment of Treg cells to a latently 
infected cell (74) would augment the effects of the immune-suppressive secretome around the latently 
infected cells dampening down CTL effector cell function [92]. Given the extremely low frequency of 
latently infected cells in a healthy seropositive individual [97], it is likely that the microenvironment 
around a latently infected cell would have little overall impact on the normal immune homeostasis of 
the bone marrow but may be locally sufficient to ensure latently infected cells evade elimination by the 
immune system. 
Induction of cIL-10 by latent virus clearly appears to be of real import for latent carriage and this 
view is, perhaps, reinforced by the fact that HCMV also encodes an IL-10 homolog, known as cmvIL-10, 
which is expressed solely during lytic infection, as well as an alternatively spliced form (LAcmvIL-10) 
expressed during both latent infection and lytic infection [98,99]. Interestingly, lytic infection-
associated cmvIL-10 has retained many of the immune-suppressive functions associated with its 
cellular counterpart [100–102] and, indeed, signals via the human IL-10 receptor [98,103]. Consistent 
with a role for cmvIL-10-mediated immune evasion are studies in rhesus CMV that have demonstrated 
a role in viral dissemination [104]—presumably via a temporary dampening of the immune response. 
It is tempting to speculate that failure to evade the immune response during a primary infection could 
profoundly impact on the set point of latency but, unfortunately, this has not been possible to analyse. 
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Figure 2. Evasion of the immune response to HCMV. The up-regulation of IL-10 in 
latently infected CD34+ cells is concomitant with TGF-b up-regulation via an unknown 
mechanism. However, the expression of two potent immune-suppressive cytokines inhibits 
the effector functions of CD4 Th1 cells recruited to a latently infected cell. Furthermore, 
both cellular IL-10 and viral IL-10 (LAcmvIL-10) act in concert to promote the  
down-regulation of HLA-DR MHC class II molecules on the surface of latently infected 
cells. Although the mechanism used by LAcmvIl-10 is not yet understood but is known not 
to occur via binding to the cellular IL-10 receptor. 
 
As stated above, the cmvIL-10 gene encodes a number of biological properties that could impinge 
on HCMV latency and reactivation. Multiple studies have shown that cmvIL-10 promotes MHC class I 
and II down-regulation [102], prevents DC maturation and function [105,106] and promotes the 
polarisation of macrophages to an M2c phenotype [107]—which is considered to be a relatively 
inactive macrophage phenotype compared with the classic inflammatory M1 phenotype. As such, all 
these functions would be consistent with a role in immune evasion. However, the alternatively spliced 
LAcmvIL-10, though also detected during lytic infection, is the isoform expressed during latent 
infection [54] but does not exhibit many of the properties of cmvIL-10 [63]—presumably, in part, due 
to its inability to bind the cIL-10 receptor [63]. Crucially, however, both latently infected GMPs and 
monocytes have been shown to exhibit a dramatic decrease in cell surface expression of MHC  
class II [32,108]—a function associated with LAcmvIL-10 [63]. Importantly the deletion of the 
UL111A locus from the virus (and thus LAcmvIL-10) has illustrated that latently cells become 
sensitive to CD4+ recognition and killing [109] as well as impacting on the normal differentiation of 
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myeloid progenitor cells to a DC phenotype [110]. Thus despite a loss of many of the functions 
associated with cmvIL-10, the LAcmvIL-10 isoform has retained biological properties that could 
contribute to successful persistence during latency in vivo. 
3.3. Viral Regulation of Immediate Early Gene Expression 
As already discussed, the regulation of HCMV MIE gene expression during latency involves the 
action of higher order chromatin structure. As such, it has been hypothesised that the assembly and 
modification of histones at the MIEP is an intrinsic response dictated by the cellular environment. 
Indeed, at low MOIs during lytic infection, there appears to be pre-immediate early gene expression 
event where the MIEP is associated with methylated histones [111]. This may well represent an  
anti-viral response to foreign DNA that is mediated by ND10 bodies and their components and is 
overcome by the action of incoming viral pp71 tegument protein and, subsequently, newly expressed 
IE72 which has been reviewed extensively elsewhere [112–114]. In contrast to lytic infection, the 
intrinsic repression of the MIEP is not overcome in non-productive myeloid cells. One study has 
proposed that unknown mechanisms that exclude pp71 from the nucleus in CD34+ cells contributes to 
this [23], although the high levels of transcriptional repressors present in these cells is also likely to be 
important; consistent with this, the transfected MIEP is intrinsically less active in undifferentiated myeloid 
cells [115]. Indeed, a number of transcriptional repressors of the MIEP have been identified (such as 
YY1 and ERF) and these are believed to recruit histone methyltransferases [116,117] to the MIEP in 
undifferentiated myeloid cells and this is important for generating the signature repressive chromatin 
phenotype associated with the MIEP of latent HCMV [11].  
However, more recent work suggests that HCMV gene products themselves may be actively 
helping to manage MIE regulation during HCMV latency. Although the prevailing view of the MIEP 
during latency in CD34+ cells is a promoter predominantly associated with repressive chromatin 
marks (i.e., histone methylation and HP-1 binding), chromatin and its post-translational modification is 
highly dynamic. Studies analysing the chromatin state of well-characterised silenced cellular genes, in 
e.g., stem cells, suggest that all cellular promoters bear at least some hallmarks of transcription [118]. 
Histone methylation at lysine 4 (a marker of a recently transcribed promoter) has been identified at 
“silent promoters” and, consistent with this, small RNA fragments were identified which would 
correspond to aborted transcription events [118]. Thus the notion of “chromatin breathing,” even at 
repressed promoters, is not uncommon. Given the potent activity of the MIEP, there is a strong 
argument that the MIEP is unlikely to be completely transcriptionally repressed, even in the most 
undifferentiated myeloid cell, and that this will call for additional mechanisms to eliminate any 
residual low level, uncontrolled MIE expression (Figure 3). 
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Figure 3. HCMV mediated repression of IE gene expression. Latent infection of CD34+ 
cells is characterised by a repression of the major immediate early promoter (MIEP). 
Classically, the MIEP has been shown to be repressed by multiple cellular transcriptional 
repressors known to interact with components of the histone modifying enzyme families. 
However, these events may be augmented by the activity of further viral mechanisms. The 
expression of LUNA during latency has been shown to be important for UL138 
expression—a protein postulated to repress the MIEP. Furthermore, the expression of the 
long non-coding 4.9kb RNA (lnc4.9 RNA) during latency has been suggested to promote 
the recruitment of polycomb repressor complex 2 (PRC2) to the MIEP via direct binding of 
the RNA. Recruitment of PRC2 would promote a chromatin structure inhibitory for MIE 
transcription. Finally, the expression of a viral miRNA, mir112.1, has been hypothesised to 
be important for silencing translation from MIE transcript UL123 during latency. 
 
During lytic infection, HCMV expresses a virally encoded microRNA (mirUL-112-1) that 
specifically target IE72 encoding UL123 transcripts [119,120] and inhibits IE72 translation [120]. 
Deletion of mirUL-112-1 has no overt phenotype in infected fibroblasts, likely due to the substantial 
levels of IE72 transcript accompanying lytic infection [120]. However, it has been postulated that low 
levels of IE72 RNA may be targeted efficiently and, hence, miRUL112-1 may have more of a role 
during latency [119]—where untimely IE72 expression could be problematic but where the less 
abundant levels of IE72 RNA could be more effectively controlled by a miRNA-mediated 
mechanisms. In effect, the microRNA acts as a safety net to ensure that the functional impact of any 
sporadic activity of the MIEP, and any resultant IE transcripts, are minimised during latent infection.  
A more recent study [25] that used a deep sequencing approach to re-visit latent gene expression in 
experimental as well as naturally latent tissue samples, identified the expression of a number of viral 
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transcripts including a 4.9 kb long non-coding RNA (lnc4.9). Interestingly, this transcript was 
observed to associate with the polycomb repressor complex 2 (PRC2)—with direct analogy to the 
KSHV PAN RNA species that also bind this complex [121]. Indeed, the PRC2 complex has also been 
shown to regulate HSV latency, although this is thought to occur independently of direct binding to the 
LAT RNA [122]. Furthermore, the binding of components of PRC2 and also the lnc4.9 RNA was 
observed in experimentally latently infected cells [25]. The net result of such interactions would be to 
augment the silencing of the viral MIEP linked with histone tri-methylation at lysine 27 on histone H3. 
The overall contribution of the lnc4.9 RNA to HCMV latency remains to be determined; however, 
analysis of whether virus mutants that fail to express lnc4.9 are defective in their establishment and 
maintenance of latency could help determine whether this interaction is as an essential component of 
the mechanisms required to maintain HCMV latency.  
Finally, other recent work has also suggested that the MIEP may repressed by a virally encoded 
factor during latency [23]. Treatment with histone deacetylase inhibitors (HDACi) is insufficient to 
promote the reactivation of IE gene expression in CD34+ cells latently infected with clinical strains of 
HCMV [23]. Conversely, however, CD34+ cells latently infected with laboratory isolates are 
responsive to HDACi. Consequently, this has suggested that a viral factor present in clinical isolates is 
involved in chromatin-mediated suppression of MIEP activity during experimental latency [23]. The 
likely candidate is UL138, which is expressed only in clinical isolates [39] and is known to be 
expressed during latent infection [34,53]. However, published studies suggest that the importance of 
UL138 for latency is not due to any direct effect on MIEP activity as a transcriptional repressor [58], 
thereby remaining in line with the predominant localisation of UL138 protein to the Golgi apparatus 
during lytic infection and transfection [58]. One caveat to this, though, is that the localisation of the 
UL138 protein has not been extensively analysed during latent infection and hence, at this stage, a role 
for UL138 in the repression of the viral MIEP during latency awaits further analyses.  
3.4. Viral Regulation of Latent Gene Expression 
In addition to the regulation of MIE gene expression, there is emerging evidence that HCMV also 
expresses functions to ensure efficient latent gene expression during latent infection (Figure 3). This, 
in itself, argues that latent viral gene products are likely to have important functions during latency 
and, importantly, that these could act as potential therapeutic targets for latent infection. 
The modulation of the cellular miRNAome during latent infection could provide potent fine-tuning 
mechanisms to optimise both viral and cellular gene expression [91]. As discussed earlier, the  
down-regulation of cellular hsa-miR-92a by HCMV is important for the increased cIL-10 production 
that results in downstream effects on viability and immune modulation [91,92]. However, the  
down-regulation of hsa-miR-92a also results in an increase in the levels of the GATA-2 transcription 
factor [91]. The GATA family of proteins are considered key regulators of haematopoiesis and 
myeloid cell production [123,124] and, thus, the targeting of this transcription factor in the knowledge 
that HCMV persists in the myeloid lineage appears more than coincidental. However, a more direct 
effect of GATA-2 regulation is observed on latent gene expression. A number of promoters of latently 
expressed genes contain consensus sequences for GATA-2 binding sites [77,91,125,126] and two of 
these, LUNA and UL144, have been directly demonstrated to be GATA-2 responsive [77,126]. Recent 
work has shown that the down-regulation of the hsa-mir92a observed in HCMV infected CD34+ cells 
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results in increased GATA-2 levels during latency, subsequently leading to increased levels of  
GATA-2-dependent latent gene expression [91].  
Although we are far from completely elucidating the function of viral gene products during latency, 
observations, to date, strongly argue that latent infection with HCMV results in a latency-associated 
transcription profile of viral gene expression, resulting in an orchestrated change in the cell to support 
latent carriage. The regulation of latent viral gene expression, as well as the role of latent viral 
functions and their effects on cellular gene expression, are clearly inextricably linked. For instance, 
recent work from the St Jeor laboratory has shown that the expression of LUNA during latent infection 
is also important for latency-associated UL138 gene expression [62]. Consequently, a pathway of 
interactions appears to occur during latency which is exemplified by latency, thus resulting in the 
targeting of cellular hsa-miR92a; this, in turn, up-regulates cellular GATA-2 expression [91], leading 
to a downstream impact on latency-associated LUNA gene expression [77,91] and ultimately ensuring 
the expression of UL138 [62], which has been proposed to be a key determinant of latency [23,53]. 
Clearly, this simplified example of a linear pathway of viral and cellular interactions is likely to 
give way to far more complex networks of host–virus interactions as we begin to understand the  
multi-functional role of viral proteins, non-coding RNAs, and miRNAs during HCMV latency and 
their impact on the latent cell.  
4. Concluding Remarks 
The advances in molecular techniques for performing large-scale analyses at the cell level are 
allowing ever more detailed analyses of aspects of HCMV biology which, previously, were all but 
impossible due the limitations of sensitivity and the availability of tractable primary cell models. These 
approaches have already begun to illustrate the complexity of HCMV latency and to provide an 
intriguing view of the concerted efforts HCMV employs to maintain the latent state.  
It is evident that the reductionist approach of these types of studies, as well as the difficulty in 
further examining in vitro findings in vivo, warrants necessary caution to prevent overinterpretation. 
Accordingly, a key development in the future of HCMV studies of latency and reactivation will be the 
tractability and applicability of the humanised mouse model to studies of HCMV [127]. Caveats with 
this system also remain; although the humanised mouse can be used to assess HCMV reactivation in 
the myeloid lineage in vivo, this is still occurring in the background of mouse tissue that does not 
support extensive HCMV replication [128]. Consequently, such analyses are, arguably, restricted to 
the very initial events of HCMV reactivation occurring within a specific niche of human cells. 
Furthermore, the extent to which the human haematopoietic system develops from engrafted human 
CD34+ cells in the mouse (for instance, murine and human cytokines do not crosstalk unequivocally) 
is unclear and, more generally, the extent to which mouse models of disease truly reflect the human 
condition is an area of ongoing debate [129,130]. Nevertheless, the humanised mouse model could 
provide the potential to examine a number of predictions regarding HCMV latency derived from in 
vitro studies, as well as certain aspects of the development of the immune response to latent HCMV.  
These cautionary notes aside, the identification of viral gene functions expressed during 
experimental latency (many of which, importantly, can be validated in naturally latent cells ex vivo) is 
beginning to provide a tantalising glimpse into the once-perceived “black box” of latency. As we begin 
to understand the functions of these latency-associated gene products, and assess their precise role in 
Viruses 2013, 5 2815 
HCMV latency and reactivation, they are also likely to become potential targets for therapeutics. These 
approaches could range from the targeting of factors important for HCMV reactivation (our own 
unpublished work suggests that the LUNA gene product may encode a function that could be a future 
therapeutic target) or for the direct targeting of latently infected cells using chemotherapeutic or 
immunotherapeutic means [61].  
Anti-viral strategies for HCMV have, to date, relied on targeting of replicating virus during lytic 
infection. However, understanding the complex interplay between the virus and the host during latency 
will give important insights into how to explore potential therapeutic options that target latent virus in 
what was previously considered to be in an “untargetable state.” 
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